This issue of the Indian Journal of Gastroenterology contains the first report from India of liver transplantation across the ABO blood group barrier [1] . ABO incompatible liver transplants have been attempted from the early days of liver transplantation in desperate situations, when the patient was unlikely to get a compatible organ in time. Since patients have circulating antibodies to the incompatible ABO antigens (isoagglutinins) and since the antigens are expressed on the endothelial cells of the graft vasculature, this typically results in an accelerated rejection which is difficult to control. The mechanisms of antibody-mediated rejection and the outcomes of such transplants were elegantly described by Demetris et al.
This issue of the Indian Journal of Gastroenterology contains the first report from India of liver transplantation across the ABO blood group barrier [1] . ABO incompatible liver transplants have been attempted from the early days of liver transplantation in desperate situations, when the patient was unlikely to get a compatible organ in time. Since patients have circulating antibodies to the incompatible ABO antigens (isoagglutinins) and since the antigens are expressed on the endothelial cells of the graft vasculature, this typically results in an accelerated rejection which is difficult to control. The mechanisms of antibody-mediated rejection and the outcomes of such transplants were elegantly described by Demetris et al. [2] from the Starzl Transplantation Institute in 1988. The antibodies bind to the graft endothelium and activate complement, which attracts and activates neutrophils and platelets and increases the permeability of the endothelium. The neutrophils exude, the platelets aggregate, and the small vessels of the graft get thrombosed, resulting in ischemic damage. This is followed by a fibrinolytic phase. This cascade tends to be inexorable once it starts. In this series, the graft survival rate within 30 days was 46 % in ABO incompatible transplants.
Despite the initial poor results, ABO incompatible liver transplants continued to be done in desperate situations, and it became apparent that outcomes in children, particularly infants, were much better than in adults and were, in fact, nearly as good as with ABO compatible transplants. These results did, however, require very profound immunosuppression. Cacciarelli et al. [3] from the Stanford University Medical Center reported a 1-and 3-year patient survival of 79 % in 14 ABO incompatible liver transplants in children. It should be noted that 12 of these 14 transplants were from blood group A donors to blood group O recipients, a combination with relatively better outcomes. These patients received ATGAM® or OKT3® for the first 7-10 days after transplant.
ABO incompatible liver transplantation really became standardized in Japan, where the scarcity of deceased donor grafts necessitated innovation in living donor transplantation. Initial results were poor there as well with a 5-year survival of 38 % in ABO incompatible liver transplants before 2001 [4] . However, living donor liver transplantation provides an opportunity to use plasmapheresis to clear preformed antibodies from the blood of the recipient. Other innovations such as adding splenectomy during the transplant, intra-arterial or intraportal infusion of methylprednisolone, prostaglandins, and gabexate mesylate led to improving outcomes. After the introduction of rituximab for depletion of B cells, these infusions (which increased the risk of vascular thrombosis) became unnecessary and 5-year survival reached 85 % in infants and 52 % in adults [5] .
The authors of the present study have adapted the Japanese protocol using plasmapheresis and rituximab in their series of three patients undergoing successful ABO incompatible liver transplants. This initial experience is encouraging, and the protocol developed by the authors serves as a starting point for others, but the results should be interpreted with caution. We do not know yet what the long-term results are going to be like, particularly in adults. The authors recently presented their updated experience at the annual conference of the Indian Association of Surgical Gastroenterology and reported five successes in six ABO incompatible liver transplants [6] . The other reported experience comes from the Amrita Institute of Medical Sciences which reported three successes in five ABO incompatible liver transplants at the same conference [7] . It should be noted that the authors of this study had an experience of over 1,000 living donor liver transplants before attempting this foray into ABO incompatible transplants. It is known (personal communications) that other centers have attempted this and have not reported adverse outcomes. This is not something that should be undertaken by centers in the early years of their learning curve.
